BlackRock Investment Management’s Crescent Biopharma CBIO Stock Holding History

BlackRock Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$232K	Hold	381	–	–	﹤0.01%	3215
2016 Q3	$272K	Buy	381 +16	+4%	+$12.2K	﹤0.01%	3201
2016 Q2	$265K	Buy	365 +349	+2,181%	+$240K	﹤0.01%	3247
2016 Q1	$10K	Hold	16	–	–	﹤0.01%	3608
2015 Q4	$9K	Hold	16	–	–	﹤0.01%	3710
2015 Q3	$9K	Hold	16	–	–	﹤0.01%	3724
2015 Q2	$13K	Buy	16 +3	+23%	+$2.48K	﹤0.01%	3610
2015 Q1	$11K	Hold	13	–	–	﹤0.01%	3617
2014 Q4	$10K	Hold	13	–	–	﹤0.01%	3678
2014 Q3	$9K	Sell	13 -1	-7%	-$809	﹤0.01%	3707
2014 Q2	$12K	Sell	14 -184	-93%	-$183K	﹤0.01%	3572
2014 Q1	$323K	Buy	+198	New	+$240K	﹤0.01%	3138

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

BlackRock Investment Management's CBIO Position: Q4 2016 in Review

BlackRock Investment Management held its Crescent Biopharma (CBIO) position steady in Q4 2016 at 381 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

BlackRock Investment Management first reported a position in CBIO in Q1 2014 and has held it in 12 quarters since. The position peaked at $323K in Q1 2014. 50 funds tracked by Wall St. Rank hold CBIO as of Q4 2016.

BlackRock Investment Management held 381 shares of Crescent Biopharma worth $232K as of Q4 2016.
BlackRock Investment Management left its Crescent Biopharma share count unchanged in Q4 2016.
Crescent Biopharma made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3215 holding.
BlackRock Investment Management first reported a position in Crescent Biopharma in Q1 2014 and has held it in 12 quarters since.
BlackRock Investment Management's Crescent Biopharma position peaked at $323K in Q1 2014.
50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.